Mark Foletta
Director/Board Member bei DEXCOM, INC.
Vermögen: 9 Mio $ am 31.03.2024
Profil
Mark G.
Foletta is currently an Independent Director at AMN Healthcare Services, Inc., Lead Independent Director at DexCom, Inc., and Independent Director at Enanta Pharmaceuticals, Inc. He is also a Member of The Financial Executives Institute and Corporate Directors Forum.
In the past, Mr. Foletta held positions as an Independent Director at Anadys Pharmaceuticals, Inc., Director at ViaCyte, Inc., Independent Director at Ambit Biosciences Corp., Independent Director at Regulus Therapeutics, Inc., Director at Islet Sciences, Inc., Chief Financial Officer & Senior VP-Finance at Amylin Pharmaceuticals, Inc., Audit Manager at Ernst & Young LLP, Chief Financial & Accounting Officer at Biocept, Inc., Chief Financial Officer & Executive Vice President at Tocagen, Inc., Chief Financial Officer, Secretary & Senior VP at Intermark, Inc., Chief Financial Officer, Secretary & Senior VP at Triton Group Ltd., and Principal at Triton Group Management, Inc.Mr. Foletta obtained his undergraduate degree from the University of California, Santa Barbara.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
DEXCOM, INC.
0,02% | 18.05.2023 | 62 398 ( 0,02% ) | 9 Mio $ | 31.03.2024 |
| 19.04.2024 | 10 254 ( 0,03% ) | 640 978 $ | 31.03.2024 | |
| 06.03.2024 | 0 ( -.--% ) | - $ | 31.03.2024 |
Aktive Positionen von Mark Foletta
| Unternehmen | Position | Beginn |
|---|---|---|
| AMN HEALTHCARE SERVICES, INC. | Director/Board Member | 12.12.2012 |
| DEXCOM, INC. | Director/Board Member | 19.11.2014 |
| ENANTA PHARMACEUTICALS, INC. | Director/Board Member | 29.06.2020 |
Corporate Directors Forum
 Corporate Directors Forum Miscellaneous Commercial ServicesCommercial Services Corporate Directors Forum operates as a forum for corporate directors. The non-profit company is based in La Jolla, CA. | Corporate Officer/Principal | - |
| The Financial Executives Institute | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Mark Foletta
| Unternehmen | Position | Ende |
|---|---|---|
ViaCyte, Inc.
 ViaCyte, Inc. Pharmaceuticals: MajorHealth Technology ViaCyte, Inc. develops a stem cell-derived islet replacement therapy for the treatment of diabetes. Its development portfolio includes VC-01 product candidate, a cell replacement therapy for the treatment of type 1 diabetes. The company was founded in 1999 and is headquartered in San Diego, CA. | Director/Board Member | 01.09.2022 |
| FORTE BIOSCIENCES, INC. | Director of Finance/CFO | 15.06.2020 |
| REGULUS THERAPEUTICS INC. | Director/Board Member | 31.05.2018 |
| BIOCEPT, INC. | Director of Finance/CFO | 27.07.2016 |
| ░░░░░ ░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
Ausbildung von Mark Foletta
| University of California, Santa Barbara | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 5 |
|---|---|
| REGULUS THERAPEUTICS INC. | Health Technology |
| AMN HEALTHCARE SERVICES, INC. | Commercial Services |
| DEXCOM, INC. | Health Technology |
| BIOCEPT, INC. | Health Technology |
| ENANTA PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 10 |
|---|---|
Amylin Pharmaceuticals, Inc.
 Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amylin Pharmaceuticals, Inc. develops and commercializes medicines for diabetes, obesity, and cardiovascular diseases. The company was founded on September 29, 1987 by Howard E. Greene, Jr. and is headquartered in San Diego, CA. | Health Technology |
Ernst & Young LLP
 Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | Commercial Services |
| The Financial Executives Institute | |
| Intermark, Inc. | Commercial Services |
Anadys Pharmaceuticals, Inc.
 Anadys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Anadys Pharmaceuticals, Inc. develops and manufactures novel small molecule medicines. It engages in developing novel medicines in the areas of hepatitis C and oncology. The firm develops ANA598, a direct-acting antiviral for the treatment of hepatitis C. The company was founded by Stelios B. Papadopoulos and Kleanthis G. Xanthopoulos in 1992 and is headquartered in Little Falls, NJ. | Health Technology |
ViaCyte, Inc.
ViaCyte, Inc. Pharmaceuticals: MajorHealth Technology ViaCyte, Inc. develops a stem cell-derived islet replacement therapy for the treatment of diabetes. Its development portfolio includes VC-01 product candidate, a cell replacement therapy for the treatment of type 1 diabetes. The company was founded in 1999 and is headquartered in San Diego, CA. | Health Technology |
Islet Sciences, Inc.
 Islet Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Islet Sciences, Inc. is a biotechnology company, which engaged in the research, development, and commercialization of new medicines and technologies for the treatment of metabolic diseases. Its product portfolio included small molecule therapeutics, islet cell transplantation, and a molecular diagnostic to detect the onset of diabetes. The company was founded on September 14, 1994 and is headquartered in Yorba Linda, CA. | Commercial Services |
Ambit Biosciences Corp.
 Ambit Biosciences Corp. Pharmaceuticals: MajorHealth Technology Ambit Biosciences Corp. develops pharmaceutical drugs. It engages in discovery, development and commercialization of small-molecule kinase inhibitors for the treatment of cancer. The firm provides drug to treat unmet medical needs in oncology, autoimmune and inflammatory diseases. The company was founded on May 17, 2000 and is headquartered in San Diego, CA. | Health Technology |
Corporate Directors Forum
Corporate Directors Forum Miscellaneous Commercial ServicesCommercial Services Corporate Directors Forum operates as a forum for corporate directors. The non-profit company is based in La Jolla, CA. | Commercial Services |
Tocagen, Inc.
 Tocagen, Inc. BiotechnologyHealth Technology Tocagen, Inc. is a clinical-stage, cancer-selective gene therapy company, which engages in the development of product candidates designed to activate a patient's immune system against their own cancer. It is in the business of discovery, development, and commercialization of products for the treatment of cancer. The company was founded by Thomas E. Darcy, Harry E. Gruber, Douglas J. Jolly, and Dennis N. Berman in August 2007 and is headquartered San Diego, CA. | Health Technology |
